Davita Clinical Research

Minneapolis, Minnesota 55404-1212

0 studies enrolling now · 72 studies all time

What they study most

Acinetobacter Baumannii Infection, Anemia, Antithrombotic, Attention Deficit Hyperactivity Disorder (ADHD), Autosomal Dominant Polycystic Kidney Disease, Binge-Eating Disorder Disorder, Calcific Uremic Arteriolopathy, Calciphylaxis, Chronic Kidney Disease, Chronic Kidney Disease Stage 5, Chronic Kidney Diseases, Clinical Pharmacology, Healthy Volunteer Study

Studies at this site

• Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition — Completed
• Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely Switch to E-vapor Products — Completed
• Clinical Evaluation of the CM-1500 During Hemodialysis — Completed
• A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. — Completed
• Phase 3 Study of SNF472 for Calciphylaxis — Completed
• Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment — Stopped early
• Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects — Completed
• A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) — Stopped early
• A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis — Completed
• Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011 — Completed
• A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function — Completed
• Effect of Hepatic Impairment on LDK378 Pharmacokinetics — Completed
• INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function — Completed
• Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. — Completed
• A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects — Completed
• Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System — Completed
• MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function — Stopped early
• Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis — Completed
• A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. — Completed
• Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function — Stopped early
• Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males — Completed
• Phase 2 Study With SNF472 in Calciphylaxis Patients — Completed
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function — Completed
• A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration — Stopped early
• DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis — Completed
• A Study of LY3113593 in Participants With Chronic Kidney Disease — Completed
• A Study of LY2928057 in Hemodialysis Participants — Completed
• A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment — Completed
• Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap — Completed
• A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis — Completed
• A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin — Completed
• Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding — Completed
• Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects — Completed
• Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD — Completed
• Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum — Completed
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects — Completed
• A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment — Completed
• Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting — Completed
• The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency — Completed
• Study to Evaluate Daptomycin Given During Dialysis and After Dialysis — Completed
• A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901 — Completed
• CSD170501: Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette — Completed
• Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) — Completed
• Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels — Completed
• Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer — Completed
• Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction — Completed
• Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C — Completed
• Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers — Completed
• Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus — Completed
• Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment — Completed